139 related articles for article (PubMed ID: 38366379)
1. The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study.
Xu Y; Luo X; Yuan B; Liang P; Liu N; Dong D; Ge W; Gu Q
J Antimicrob Chemother; 2024 Apr; 79(4):820-825. PubMed ID: 38366379
[TBL] [Abstract][Full Text] [Related]
2. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
[TBL] [Abstract][Full Text] [Related]
3. A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance.
Xu Y; Tang J; Yuan B; Luo X; Liang P; Liu N; Dong D; Jin L; Ge W; Gu Q
Pharmacol Res Perspect; 2024 Feb; 12(1):e01163. PubMed ID: 38149723
[TBL] [Abstract][Full Text] [Related]
4. Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Gatti M; Rinaldi M; Bonazzetti C; Gaibani P; Giannella M; Viale P; Pea F
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0096923. PubMed ID: 37843260
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections.
Fresan D; Luque S; Benítez-Cano A; Sorlí L; Milagro Montero M; De-Antonio M; Prim N; Vega V; Horcajada JP; Grau S
J Antimicrob Chemother; 2023 Mar; 78(3):678-683. PubMed ID: 36626402
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
10. Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.
Iosifidis E; Chorafa E; Agakidou E; Kontou A; Violaki A; Volakli E; Christou EI; Zarras C; Drossou-Agakidou V; Sdougka M; Roilides E
Pediatr Infect Dis J; 2019 Aug; 38(8):812-815. PubMed ID: 31135647
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
Zhao X; Li S; Zhang Y; Wang J; Wang C; Qin X; Hu F; Wang M
Int J Antimicrob Agents; 2023 May; 61(5):106777. PubMed ID: 36905946
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
Sy SKB; Zhuang L; Sy S; Derendorf H
Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
[TBL] [Abstract][Full Text] [Related]
14. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
Balandín B; Ballesteros D; Pintado V; Soriano-Cuesta C; Cid-Tovar I; Sancho-González M; Pérez-Pedrero MJ; Chicot M; Asensio-Martín MJ; Silva JA; de Luna RR; Gesso CM; Rodríguez-Serrano DA; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2022 Mar; 59(3):106536. PubMed ID: 35091054
[TBL] [Abstract][Full Text] [Related]
15. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF).
Gatti M; Rinaldi M; Gaibani P; Siniscalchi A; Tonetti T; Giannella M; Viale P; Pea F
J Crit Care; 2023 Aug; 76():154301. PubMed ID: 37059003
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S
Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
Onorato L; Di Caprio G; Signoriello S; Coppola N
Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the clinical application of ceftazidime-avibactam in China.
Wang Q; Xu P; Zhou Y
J Infect Public Health; 2022 Apr; 15(4):455-459. PubMed ID: 35216921
[TBL] [Abstract][Full Text] [Related]
20. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
Nichols WW; Bradford PA; Stone GG
J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
